((1S,2R)-2-Methyl-cyclopentyl)-methanol | 64681-42-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ((1S,2R)-2-Methyl-cyclopentyl)-methanol
• 英文别名: [(1S,2R)-2-methylcyclopentyl]methanol
• CAS: 64681-42-1
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: YZDHUYYBHHBWMD-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1S,2R)-2-Methyl-cyclopentanecarboxylic acid (1R,2S,5R)-5-methyl-2-(1-methyl-1-phenyl-ethyl)-cyclohexyl ester 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 ((1S,2R)-2-Methyl-cyclopentyl)-methanol
  参考文献：
  名称：

  Stereogenic reactions of the α-carbon radicals of 8-phenylmenthyl esters

  摘要：

  描述了 8-苯基苯甲酯的立体选择性自由基还原和环化过程；主要产物被认为来自于具有与酯的烷氧基对立的较大取代基构象的过渡态。

  DOI：

  10.1039/c39910001603

文献信息

• Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use
  申请人：PIMCO 2664 Limited

  公开号：US20150141472A1

  公开（公告）日：2015-05-21

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

  本发明通常涉及治疗化合物领域，更具体地涉及以下式（统称为“APSAC化合物”）的某些芳基-苯基-磺酰胺基-环烷基化合物。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物在治疗中的使用，包括体外和体内，例如治疗炎症和/或关节破坏和/或骨量减少；治疗由免疫系统过度和/或不适当和/或持续激活介导的疾病；治疗炎症和自身免疫性疾病，例如类风湿性关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等；治疗与骨量减少相关的疾病，例如类风湿性关节炎中由过度破骨细胞活性引起的骨量减少、骨质疏松症、癌症相关骨病、帕吉特病等；以及治疗癌症，例如血液恶性肿瘤、实体瘤等。
• [EN] AMINOHETEROARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE AMINOHÉTÉROARYLE
  申请人：ANRUI BIOMEDICAL TECH GUANGZHOU CO LTD

  公开号：WO2022111621A1

  公开（公告）日：2022-06-02

  Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.

  本文提供了新型化合物（例如，公式I或II），制药组合物和使用方法，涉及到细胞周期蛋白依赖性激酶（CDKs）。这些化合物通常是CDK2抑制剂，可用于治疗各种疾病或障碍，例如癌症。
• A Model Study of Intramolecular Asymmetric Radical Cyclizations of α-Ester and α-Amide Radicals
  作者：Ru-Long Yeh、Weir-Tom Jiaang、Yeun-Min Tsai

  DOI：10.1002/jccs.199700039

  日期：1997.6

  AbstractStarting from malonate, a practical route was developed for the synthesis of α‐phenylthio acid 3. Several chiral compounds including (‐)‐menthol, (‐)‐8‐pbenylmenthol and a camphor based oxazolidinone 8 reacted with 3 to give α‐phenylthio esters or amide. These sulfides cyclized efficiently when reacted with tributyltin hydride. Among the chiral auxiliaries used, 8‐phenylmenthyl group displayed moderate asymmetric induction (64% ee for cis‐product and 40% ee for trans‐product). Based on this results, a transition state model was proposed to explain the observed stereoselectivity. In this model, due to π,π‐orbital overlap of the phenyl ring and the carbonyl, the si‐face of the most stable conformer of the radical was shielded. This controlled the carbon‐carbon bond formation to occur from the re‐face.
• ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE
  申请人：Pimco 2664 Limited

  公开号：EP2344449B1

  公开（公告）日：2015-05-13
• US9616037B2
  申请人：——

  公开号：US9616037B2

  公开（公告）日：2017-04-11